dc.creatorLlavero, Francisco
dc.creatorSastre, Alazne Arrazola
dc.creatorMontoro, Miriam Luque
dc.creatorGálvez, Patricia
dc.creatorLacerda, Hadriano M.
dc.creatorParada, Luis Antonio
dc.creatorZugaza, José Luis
dc.date.accessioned2020-11-09T18:48:05Z
dc.date.accessioned2022-10-15T13:02:12Z
dc.date.available2020-11-09T18:48:05Z
dc.date.available2022-10-15T13:02:12Z
dc.date.created2020-11-09T18:48:05Z
dc.date.issued2019-12
dc.identifierLlavero, Francisco; Sastre, Alazne Arrazola; Montoro, Miriam Luque; Gálvez, Patricia; Lacerda, Hadriano M.; et al.; Mcardle disease: New insights into its underlying molecular mechanisms; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 20; 23; 12-2019; 1-15
dc.identifier1422-0067
dc.identifierhttp://hdl.handle.net/11336/117964
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4389025
dc.description.abstractMcArdle disease, also known as glycogen storage disease type V (GSDV), is characterized by exercise intolerance, the second wind phenomenon, and high serum creatine kinase activity. Here, we recapitulate PYGM mutations in the population responsible for this disease. Traditionally, McArdle disease has been considered a metabolic myopathy caused by the lack of expression of the muscle isoform of the glycogen phosphorylase (PYGM). However, recent findings challenge this view, since it has been shown that PYGM is present in other tissues than the skeletal muscle. We review the latest studies about the molecular mechanism involved in glycogen phosphorylase activity regulation. Further, we summarize the expression and functional significance of PYGM in other tissues than skeletal muscle both in health and McArdle disease. Furthermore, we examine the different animal models that have served as the knowledge base for better understanding of McArdle disease. Finally, we give an overview of the latest state-of-the-art clinical trials currently being carried out and present an updated view of the current therapies.
dc.languageeng
dc.publisherMolecular Diversity Preservation International
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3390/ijms20235919
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/20/23/5919
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGLYCOGEN PHOSPHORYLASE
dc.subjectGLYCOGEN STORAGE DISEASE TYPE V
dc.subjectHEXOSAMINE BIOSYNTHETIC PATHWAY
dc.subjectMCARDLE DISEASE
dc.subjectO-GLYCOSYLATION
dc.subjectSMALL GTPASES
dc.titleMcardle disease: New insights into its underlying molecular mechanisms
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución